Chronic Pain and Psychedelic-Assisted Therapy in Canada

Chronic pain — pain persisting beyond normal tissue healing time, typically defined as >3 months — affects roughly 1 in 5 Canadians (Statistics Canada CCHS; Public Health Agency of Canada). Specific syndromes include complex regional pain syndrome (CRPS), fibromyalgia, neuropathic pain (diabetic neuropathy, post-herpetic neuralgia, central pain), chronic low back pain, chronic migraine and cluster headache, chronic pelvic pain, and chronic post-surgical pain. Standard-of-care multimodal pain management — physiotherapy, CBT for pain, gabapentinoids, SNRIs, opioids (selectively), interventional procedures (nerve blocks, epidurals, neuromodulation) — is foundational. This article is a Canadian evidence-and-pathway guide to psychedelic-assisted therapy as adjunct or alternative: off-label ketamine with substantial RCT evidence in CRPS, neuropathic pain, and fibromyalgia (Schwartzman 2009, Sigtermans 2009, Noppers 2010, Niesters 2014); psilocybin emerging in cluster headache (Sewell 2006 historical; Schindler 2022 cluster headache pilot); WSIB Ontario's Chronic Pain Disability formulary covers ketamine for compensable chronic pain; VAC mental-health benefits cover ketamine for service-related chronic pain. Importantly, psychedelic-assisted therapy does NOT replace comprehensive multidisciplinary pain management.

Key takeaways

• Chronic pain affects ~1 in 5 Canadians. Major syndromes: CRPS, fibromyalgia, neuropathic pain, chronic low back, chronic migraine/cluster headache, chronic pelvic, chronic post-surgical.
• Multimodal pain management is foundational: physiotherapy, CBT for pain, gabapentinoids, SNRIs, opioids (selectively), interventional procedures.
• Off-label ketamine for chronic pain has substantial RCT base: Schwartzman 2009 (CRPS), Sigtermans 2009 (CRPS), Noppers 2010, Niesters 2014 (fibromyalgia review), Cohen 2018 (chronic pain consensus).
• WSIB (Ontario's Workplace Safety and Insurance Board) Ontario Chronic Pain Disability formulary: ketamine and esketamine listed; meaningful pathway for compensable chronic pain.
• Psilocybin for cluster headache: emerging evidence — Sewell 2006 Neurology; Schindler 2022 cluster headache pilot.
• VAC (Veterans Affairs Canada): ketamine established for service-related chronic pain.
• Public hospital ketamine programs with chronic pain anchor: Edmonton's Misericordia/Grey Nuns; Vancouver UBC Hospital; St. Joseph's London ON IV ketamine for chronic pain (CRPS) only.
• No psychedelic-assisted therapy is Health Canada-approved for chronic pain. Spravato is approved for TRD only.
• Psychedelic-assisted therapy does NOT replace multimodal pain management — appropriately considered as adjunct.

Defining chronic pain syndromes

Major chronic pain syndromes addressed in this article:

• Complex Regional Pain Syndrome (CRPS) Type I (RSD) and Type II (causalgia): regional, often-disproportionate pain after injury; trophic changes, autonomic dysregulation
• Fibromyalgia: widespread musculoskeletal pain, fatigue, sleep disturbance; ACR 2016 criteria
• Neuropathic pain: pain from injury to the somatosensory nervous system — diabetic peripheral neuropathy, post-herpetic neuralgia, central post-stroke pain, spinal cord injury pain
• Chronic low back pain: persistent LBP beyond 3 months
• Chronic migraine and cluster headache: cluster headache is one of the most severe pain syndromes; chronic migraine ≥15 days/month for ≥3 months
• Chronic pelvic pain: endometriosis-related, interstitial cystitis, vulvodynia
• Chronic post-surgical pain: persistent pain >3 months post-surgery

The chronic pain evidence map for psychedelic-assisted therapy

Off-label ketamine — strongest evidence base in chronic pain

• Schwartzman RJ, Alexander GM, Grothusen JR, et al. 2009 (PMID 20021588): outpatient IV ketamine for CRPS. Significant pain reduction at 3 months.
• Sigtermans MJ, van Hilten JJ, Bauer MC, et al. 2009 (PMID 19748191): inpatient ketamine infusion for CRPS Type I. Significant pain reduction sustained at 12 weeks.
• Noppers I, Niesters M, Aarts L, et al. 2010: review of IV ketamine for chronic pain.
• Niesters M, Martini C, Dahan A. 2014 (PMID 24248536): ketamine for chronic pain — including fibromyalgia review.
• Cohen SP, Bhatia A, Buvanendran A, et al. 2018 (PMID 29870457): consensus guidelines on intravenous ketamine for chronic pain (American Society of Regional Anesthesia + American Academy of Pain Medicine + American Society of Anesthesiologists).
• Maher DP, Chen L, Mao J. 2017 (PMID 28683081): ketamine and chronic pain comprehensive review.

Psilocybin — emerging in cluster headache

• Sewell RA, Halpern JH, Pope HG. 2006 (PMID 16801660): historical case-series report in Neurology of psilocybin and LSD for cluster headache; suggested cluster cycle interruption.
• Schindler EAD, Sewell RA, Gottschalk CH, et al. 2022 (PMID 36284054): pilot RCT of psilocybin for cluster headache; small sample but signal.
• Yale University cluster headache program: ongoing research with psilocybin.

Spravato and MDMA — NOT for chronic pain

Spravato is approved for TRD only. MDMA-AT is investigational for PTSD only. Neither is approved or investigational for chronic pain.

For more detail see Ketamine Therapy for Chronic Pain and the Ketamine Therapy in Canada guide.

Decision framework — multimodal pain integration

Psychedelic-assisted therapy for chronic pain is appropriately considered as adjunct to multimodal pain management, not a replacement. The decision framework typically considers:

Canadian access pathways

Multimodal pain management

• Provincial pain programs: most provinces have publicly funded multidisciplinary pain centres (often hospital-based or academic-affiliated)
• Pain Society of Canada / Canadian Pain Society practitioner directory
• WSIB and WCB programs: comprehensive chronic pain disability programs

Off-label ketamine for chronic pain

• WSIB Ontario Chronic Pain Disability formulary: ketamine and esketamine listed
• WCB Alberta: case-by-case for compensable chronic pain
• VAC: established case-by-case for service-related chronic pain
• Public hospital programs:
  • Edmonton Misericordia/Grey Nuns: publicly funded outpatient ketamine including pain indications
  • Vancouver UBC Hospital VCH program: includes pain
  • St. Joseph's Health Care London: IV ketamine infusion for chronic pain (CRPS) only — not psychiatric
• Private: ~$400–$1,500/session

For more detail see Workers' Compensation for Psychedelic-Assisted Therapy, Edmonton Misericordia/Grey Nuns Public Ketamine, and VAC Coverage for Psychedelic-Assisted Therapy.

Psilocybin SAP for cluster headache

• Pathway: prescribing physician submits Health Canada SAP application
• Cluster headache is a recognized SAP indication; some Canadian neurologists are increasingly familiar
• Supply: Filament Health no-charge SAP psilocybin or other licensed supplier
• Clinical capacity: smaller than for end-of-life distress; emerging

For more detail see the Psilocybin Therapy in Canada guide.

What the evidence does NOT say

• No psychedelic-assisted therapy is approved for chronic pain in Canada.
• Ketamine for chronic pain has dose-response and tolerance considerations. Sustained-effect maintenance is variable; some patients require ongoing infusions, others have sustained benefit from a series.
• Cluster headache evidence is emerging, not pivotal. Schindler 2022 was a small pilot; substantial phase 3 evidence does not yet exist.
• Multimodal pain management is foundational. Patients with severe chronic pain typically benefit from comprehensive pain medicine including physiotherapy, CBT for pain, pharmacology, and interventional procedures.
• Safety considerations: cardiovascular screening for ketamine; psychotic-disorder personal/family history excludes psilocybin; substance-use considerations particularly for opioid-dependent chronic pain populations; concurrent SSRIs/SNRIs require attention with serotonergic psychedelics.
• Opioid use considerations: chronic pain patients on stable opioid regimens require coordination — ketamine has been studied as opioid-sparing, but interactions and tapering require close pain medicine coordination.

How ATMA CENA works with chronic pain patients

ATMA CENA's chronic pain pathway:

• Comprehensive intake: pain history, prior treatments, current pain medication regimen, comorbidities (depression often comorbid), medical screen
• Pain medicine coordination: ATMA CENA's care model keeps the patient's pain medicine specialist in the primary therapeutic relationship; ATMA CENA layers ketamine-assisted protocol on top
• Three-phase model: preparation + dosing + integration — particularly important for chronic pain populations
• Honest framing: ATMA CENA is not a primary pain clinic. Chronic pain patients with established multimodal pain management benefit from psychedelic-assisted therapy as adjunct, not replacement.

For more detail see Ketamine Therapy for Chronic Pain.

Frequently asked questions

What's the strongest ketamine chronic pain evidence? Schwartzman 2009 outpatient IV ketamine for CRPS; Sigtermans 2009 inpatient ketamine for CRPS Type I; Cohen 2018 consensus guidelines on IV ketamine for chronic pain. Substantial RCT base for CRPS specifically; meaningful evidence for neuropathic pain and fibromyalgia.

Is ketamine effective for fibromyalgia? Niesters 2014 review summarizes ketamine for chronic pain including fibromyalgia. Smaller-scale evidence than CRPS. Some patients report sustained benefit; sustained-effect data are mixed.

What's the deal with psilocybin and cluster headache? Sewell 2006 Neurology historical case series suggested psilocybin and LSD interrupted cluster cycles. Schindler 2022 pilot RCT showed signal. Cluster headache is among the most severe pain syndromes; psilocybin remains investigational under SAP for this indication.

Does WSIB cover ketamine for chronic pain? Yes — WSIB Ontario Chronic Pain Disability formulary lists ketamine and esketamine for compensable chronic pain. Bill 163 presumptive PTSD legislation accelerates first-responder eligibility for compensable conditions.

What about veterans with chronic pain? VAC mental-health and treatment benefits cover ketamine for service-related chronic pain (case-by-case with documentation). Strong pathway for veterans with service-related CRPS, neuropathic pain, or chronic post-injury pain.

What if I'm on opioids? Chronic pain patients on stable opioid regimens require coordination. Ketamine has been studied as opioid-sparing — but interactions, tapering, and pain medicine coordination are essential. Do not interrupt your opioid regimen without your pain medicine team.

What about Spravato for pain? Spravato is Health Canada-approved for TRD only — not for chronic pain. Off-label use for pain is rare given off-label generic ketamine has more direct evidence.

Is there a public hospital ketamine pain program? Yes, several:

• Edmonton Misericordia/Grey Nuns: publicly funded outpatient ketamine including pain
• Vancouver UBC Hospital VCH program
• St. Joseph's Health Care London: IV ketamine infusion for chronic pain (CRPS) only

What's the cost?

• Off-label IV ketamine: ~$500–$1,500/session
• Off-label IM/SL ketamine: ~$400–$900/session
• Psilocybin SAP for cluster headache: variable; supply via Filament Health no-charge SAP option exists; clinical hours separate
• WSIB / VAC pathways may cover for eligible patients

Is psychedelic-assisted therapy a replacement for nerve blocks or other procedures? No. Psychedelic-assisted therapy is appropriately considered as adjunct to comprehensive pain medicine — not a replacement for interventional procedures, neuromodulation, or surgical interventions when those are clinically indicated.

Sources

1. Schwartzman RJ, Alexander GM, Grothusen JR, et al. (2009). Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. Pain, 147(1-3):107-115. PMID: 20021588.
2. Sigtermans MJ, van Hilten JJ, Bauer MC, et al. (2009). Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain, 145(3):304-311. PMID: 19748191.
3. Niesters M, Martini C, Dahan A. (2014). Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol, 77(2):357-67. PMID: 24248536.
4. Cohen SP, Bhatia A, Buvanendran A, et al. (2018). Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med, 43(5):521-546. PMID: 29870457.
5. Maher DP, Chen L, Mao J. (2017). Intravenous Ketamine Infusions for Neuropathic Pain Management: A Promising Therapy in Need of Optimization. Anesth Analg, 124(2):661-674. PMID: 28067704.
6. Sewell RA, Halpern JH, Pope HG. (2006). Response of cluster headache to psilocybin and LSD. Neurology, 66(12):1920-2. PMID: 16801660.
7. Schindler EAD, Sewell RA, Gottschalk CH, et al. (2022). Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Neurotherapeutics, 18(1):534-543. PMID: 36284054.
8. Niesters M, Khalili-Mahani N, Martini C, et al. (2012). Effect of subanesthetic ketamine on intrinsic functional brain connectivity: a placebo-controlled functional magnetic resonance imaging study in healthy male volunteers. Anesthesiology, 117(4):868-77. PMID: 22890118.
9. Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
10. WSIB Ontario — Ketamine and Esketamine Formulary Decision: https://www.wsib.ca/en/drug-formulary-listing-decision-ketamine-and-esketamine
11. WSIB Ontario — Chronic Pain Disability formulary: https://www.wsib.ca/en/businesses/health-and-safety/programs-and-policies-supporting-injured-workers
12. Veterans Affairs Canada — Mental Health Benefits: https://www.veterans.gc.ca/en/financial-programs-and-services/medical-costs/coverage-services-prescriptions-and-devices/mental-health-benefits
13. Canadian Pain Society: https://www.canadianpainsociety.ca/
14. St. Joseph's Health Care London — IV Ketamine Infusion: https://www.sjhc.london.on.ca/patients-and-visitors/online-patient-and-caregiver-resource-library/iv-ketamine-infusion

Related articles

• Ketamine Therapy for Chronic Pain
• Workers' Compensation for Psychedelic-Assisted Therapy
• VAC Coverage for Psychedelic-Assisted Therapy
• Edmonton Misericordia/Grey Nuns Public Ketamine
• Treatment-Resistant Depression and Psychedelic-Assisted Therapy
• PTSD and Psychedelic-Assisted Therapy
• Insurance Coverage for Psychedelic-Assisted Therapy in Canada
• Ketamine Therapy in Canada

Last updated: 2026-05-06